Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Arm Phase 2 Clinical Trial Of Regorafenib in Patients With Multiply Recurrent Epithelial Ovarian Cancer

NCT02736305 is registered in ClinicalTrials.gov with National Cancer Centre, Singapore as lead sponsor.

NCT NCT02736305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02736305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Arm Phase 2 Clinical Trial Of Regorafenib in Patients With Multiply Recurrent Epithelial Ovarian Cancer
Lead sponsor
National Cancer Centre, Singapore
Phase
Phase 2
Overall status
Completed
Start date
February 3, 2016
Completion date
November 18, 2019
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian neoplasms